C-Reactive Protein (CRP) in Obese Diabetic Women

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Rosuvastatin; improvement of lipid profile

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00262548

D3560L00018

DM-CRESTOR-0001

Details and patient eligibility

About

The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.

Enrollment: 100 estimated patients

Sex: Female

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Menopausal
• Diagnosed diabetes mellitus type 2
• Obese (body mass index [BMI] > 25 ≤ 30)

Exclusion criteria

• Fasting blood glucose ≥ 200 mg/dl
• CRP < 2 mg/L and > 10 mg/L

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind